journal
https://read.qxmd.com/read/32991794/safety-and-immunogenicity-of-sars-cov-2-mrna-1273-vaccine-in-older-adults
#1
Evan J Anderson, Nadine G Rouphael, Alicia T Widge, Lisa A Jackson, Paul C Roberts, Mamodikoe Makhene, James D Chappell, Mark R Denison, Laura J Stevens, Andrea J Pruijssers, Adrian B McDermott, Britta Flach, Bob C Lin, Nicole A Doria-Rose, Sijy O'Dell, Stephen D Schmidt, Kizzmekia S Corbett, Phillip A Swanson, Marcelino Padilla, Kathy M Neuzil, Hamilton Bennett, Brett Leav, Mat Makowski, Jim Albert, Kaitlyn Cross, Venkata Viswanadh Edara, Katharine Floyd, Mehul S Suthar, David R Martinez, Ralph Baric, Wendy Buchanan, Catherine J Luke, Varun K Phadke, Christina A Rostad, Julie E Ledgerwood, Barney S Graham, John H Beigel
BACKGROUND: Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age. METHODS: We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults...
September 29, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32970396/dapagliflozin-in-patients-with-chronic-kidney-disease
#2
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing, C David Sjöström, Roberto D Toto, Anna-Maria Langkilde, David C Wheeler
BACKGROUND: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known. METHODS: We randomly assigned 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo...
September 24, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32966717/tribal-truce-how-can-we-bridge-the-partisan-divide-and-conquer-covid
#3
Lisa Rosenbaum
No abstract text is available yet for this article.
September 23, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32966716/evaluating-and-deploying-covid-19-vaccines-the-importance-of-transparency-scientific-integrity-and-public-trust
#4
Jason L Schwartz
No abstract text is available yet for this article.
September 23, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32966715/community-health-workers-and-covid-19-addressing-social-determinants-of-health-in-times-of-crisis-and-beyond
#5
Patricia J Peretz, Nadia Islam, Luz Adriana Matiz
No abstract text is available yet for this article.
September 23, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32966714/cardiovascular-outcomes-with-ertugliflozin-in-type-2-diabetes
#6
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino, Weichung J Shih, Ira Gantz, Steven G Terra, David Z I Cherney, Darren K McGuire
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)...
September 23, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32966713/loss-of-anti-sars-cov-2-antibodies-in-mild-covid-19-reply
#7
LETTER
Otto O Yang, F Javier Ibarrondo
No abstract text is available yet for this article.
September 23, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32961043/the-path-forward-an-antiracist-approach-to-academic-medicine
#8
Hisham Yousif, Nworah Ayogu, Taison Bell
No abstract text is available yet for this article.
September 22, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32960514/once-weekly-insulin-for-type-2-diabetes-without-previous-insulin-treatment
#9
Julio Rosenstock, Harpreet S Bajaj, Andrej Janež, Robert Silver, Kamilla Begtrup, Melissa V Hansen, Ting Jia, Ronald Goldenberg
BACKGROUND: It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes. METHODS: We conducted a 26-week, randomized, double-blind, double-dummy, phase 2 trial to investigate the efficacy and safety of once-weekly insulin icodec as compared with once-daily insulin glargine U100 in patients who had not previously received long-term insulin treatment and whose type 2 diabetes was inadequately controlled (glycated hemoglobin level, 7...
September 22, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32955176/kras-g12c-inhibition-with-sotorasib-in-advanced-solid-tumors
#10
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger, Yung-Jue Bang, Grace K Dy, John C Krauss, Yasutoshi Kuboki, James C Kuo, Andrew L Coveler, Keunchil Park, Tae Won Kim, Fabrice Barlesi, Pamela N Munster, Suresh S Ramalingam, Timothy F Burns, Funda Meric-Bernstam, Haby Henary, Jude Ngang, Gataree Ngarmchamnanrith, June Kim, Brett E Houk, Jude Canon, J Russell Lipford, Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T Li
BACKGROUND: No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C . METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily...
September 20, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32955175/one-step-at-a-time-clinical-evidence-that-kras-is-indeed-druggable
#11
EDITORIAL
Patricia M LoRusso, Judith S Sebolt-Leopold
New England Journal of Medicine, Volume 383, Issue 13, Page 1277-1278, September 2020.
September 20, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32955174/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer
#12
Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Guilhem Roubaud, Mustafa Özgüroğlu, Jinyu Kang, Joseph Burgents, Christopher Gresty, Claire Corcoran, Carrie A Adelman, Johann de Bono
BACKGROUND: We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis of overall survival have not yet been reported...
September 20, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32955177/osimertinib-in-resected-egfr-mutated-non-small-cell-lung-cancer
#13
Yi-Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohe, Margarita Majem, Jonathan W Goldman, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lu, Kye-Young Lee, Charuwan Akewanlop, Chong-Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S Herbst
BACKGROUND: Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor ( EGFR ) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown. METHODS: In this double-blind, phase 3 trial, we randomly assigned patients with completely resected EGFR mutation-positive NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once daily) or placebo for 3 years...
September 19, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32945632/avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma
#14
Thomas Powles, Se Hoon Park, Eric Voog, Claudia Caserta, Begoña P Valderrama, Howard Gurney, Haralabos Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N Sternberg, Joaquim Bellmunt, Jeanny B Aragon-Ching, Daniel P Petrylak, Robert Laliberte, Jing Wang, Bo Huang, Craig Davis, Camilla Fowst, Nuno Costa, John A Blake-Haskins, Alessandra di Pietro, Petros Grivas
BACKGROUND: Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. METHODS: In a phase 3 trial, we randomly assigned patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (four to six cycles of gemcitabine plus cisplatin or carboplatin) to receive best supportive care with or without maintenance avelumab...
September 18, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32937063/a-pandemic-within-a-pandemic-intimate-partner-violence-during-covid-19
#15
Megan L Evans, Margo Lindauer, Maureen E Farrell
No abstract text is available yet for this article.
September 16, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32937062/detection-of-sars-cov-2-with-sherlock-one-pot-testing
#16
LETTER
Julia Joung, Alim Ladha, Makoto Saito, Nam-Gyun Kim, Ann E Woolley, Michael Segel, Robert P J Barretto, Amardeep Ranu, Rhiannon K Macrae, Guilhem Faure, Eleonora I Ioannidi, Rohan N Krajeski, Robert Bruneau, Meei-Li W Huang, Xu G Yu, Jonathan Z Li, Bruce D Walker, Deborah T Hung, Alexander L Greninger, Keith R Jerome, Jonathan S Gootenberg, Omar O Abudayyeh, Feng Zhang
No abstract text is available yet for this article.
September 16, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32937061/the-human-touch-addressing-health-care-s-workforce-problem-amid-the-pandemic
#17
Eli M Cahan, Lisa B Levine, William W Chin
No abstract text is available yet for this article.
September 16, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32937060/what-values-and-priorities-mean-for-health-reform
#18
Katherine Baicker, Amitabh Chandra
No abstract text is available yet for this article.
September 16, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32931679/bridging-the-gap-at-warp-speed-delivering-options-for-preventing-and-treating-covid-19
#19
Moncef Slaoui, Shannon E Greene, Janet Woodcock
No abstract text is available yet for this article.
September 15, 2020: New England Journal of Medicine
https://read.qxmd.com/read/32931162/up-is-down-pharmaceutical-industry-caution-vs-federal-acceleration-of-covid-19-vaccine-approval
#20
Jerry Avorn, Aaron S Kesselheim
No abstract text is available yet for this article.
September 15, 2020: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"